The U.S. National Cancer Institute (NCI) Cancer Moonshot Biobank launched in September 2020, with the aim of accelerating cancer research by creating a resource of well-annotated, longitudinal cancer biospecimens from […] Read more
In recent years, precision medicine has begun to play an increasingly important role in cancer care. Advanced diagnostic testing, including testing for somatic mutations, non-genomic biomarkers, and germline mutations, is […] Read more
The immune checkpoint inhibitors (ICIs) monotherapy has resulted in significant improvements in PFS and OS in advanced NSCLC when compared with chemotherapy alone, and it has become the standard of […] Read more
In February 2021, the American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) published a joint guideline update to the 2017 ASCO guidelines regarding systemic therapy for […] Read more
Because nearly one-half of patients with advanced cancer are eligible for immune checkpoint inhibitor (ICI)–based treatment, these therapies are now in widespread clinical use.1 ICIs—whether as monotherapy, in checkpoint inhibitor […] Read more
In Reference To: Tian S, Switchenko JM, Buchwald ZS, et al. Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis. Int J Radiat Oncol Biol Phys. 2020;108(1):304-313. Read more
“Pierre was not only an amazing physician and scientist, but he was also a truly amazing, kind, generous, and loving soul who always had a smile on his face and a kind word for everyone he met.” Read more
With multiple new therapies available, Prof. Johan Vansteenkiste says the search is on for biomarkers to better match patients to treatments. Read more
Could the Daunting Biology of Small-Cell Lung Cancer Provide the Key to Elucidating Drug Resistance?
At ELCC 2021, Prof. Fiona Blackhall sees hope for improving patients’ poor prognoses on the horizon. Read more
When compensating participants in clinical trials, the objective is to show appreciation and consideration for a patient’s time and expenses without exerting undue influence. The Office for Human Research Protections […] Read more